Abbott revealed new data showing a significant rise in diabetic ketoacidosis (DKA) hospitalizations across all age groups in the U.S., especially among children with Type 1 diabetes. DKA, a dangerous condition caused by high ketone levels due to insufficient insulin, is often hard to detect early because symptoms mimic common illnesses and ketone monitoring is not routine. Abbott introduced a dual glucose-ketone sensor system, Libre Duo, approved in Europe and pending FDA clearance in the U.S., aiming to help patients detect rising ketones earlier and reduce costly hospital stays. This innovation addresses a critical gap in diabetes care by combining continuous glucose and ketone monitoring in one device.
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
A U.S. federal judge ruled that Abbott Laboratories' marketing of PediaSure could reasonably be interpreted as promising height growth, despite the company's claims focusing on general growth. The judge noted product packaging and advertising featuri...
The global market for non-invasive blood glucose monitoring devices, which measure blood sugar without needles, is projected to grow from $34.86 million in 2024 to $340.49 million by 2034, at a CAGR of 25.6%. Growth is fueled by the increasing diabet...
The global peripheral vascular devices market is projected to grow from $10.02 billion in 2026 to $13.22 billion by 2031, at a CAGR of 5.7%. Growth is fueled by rising cases of vascular disorders linked to aging, diabetes, and lifestyle factors, alon...
